Skip to Main Content
Diseases of the Cardiovascular System

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

What is the purpose of this trial?

This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).

Contact Information

For more information about this study, including how to volunteer, contact Christopher Maulion, MD

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    10/01/2024
  • Study HIC
    #2000028712